For the first time, Wellcome's aciclovir faces tough competition as an antiviral treatment for herpes zoster (shingles). The competition comes in the form of SmithKline Beecham's new drug famciclovir [Famvir®]. If its claimed advantages are seen in practice, this drug may whittle away the monopoly held by aciclovir.